DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Griscelli syndrome — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGriscelli syndrome maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for griscelli syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
RAB27A, member RAS oncogene family (RAB27A) — RAB27A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9LA9 · 4.38 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
A 2010 case report describes a preterm neonate with respiratory distress, intracerebral haemorrhage, and silvery-grey hair who was diagnosed with Griscelli syndrome type 3 after a novel homozygous mutation in the melanophilin gene was found. The authors state that only the hypopigmentation, not the other clinical features, was attributable to GS type 3, and they stress that differential diagnosis between GS subtypes must be done early because GS type 2 is associated with a life-threatening but curable immune disorder. A 2019 report of a 23-year-old male with GS type 3 describes it as a mild variant with only pigmentary dilution and excellent prognosis, the least reported subtype.
A 2021 report describes a 7-year-old girl who initially presented with fever and pancytopenia; malignancies were ruled out and she was treated for an infectious disease and discharged, but developed new symptoms ten days later. Microscopic hair shaft analysis showed abnormal pigment distribution, indicating GS. A 2007 report describes a 20-year-old female with GS who had diffuse pigment dilution plus circumscribed pigment loss over the thighs and abdomen, and who experienced an accelerated phase with neurological deterioration. The authors note that GS is usually fatal by the first decade of life and that survival beyond that in the absence of specific therapy was a distinctive feature in this case.
A 2016 article notes that GS is caused by mutations in any of three genes encoding a tripartite protein complex essential for melanosome transport. GS1 presents with hypomelanosis and primary neurological defects and is caused by mutations in MYO5A. The article is behind a paywall and no further clinical data are available from the abstract.
What remains missing is any controlled trial of a specific therapy for any GS subtype. The literature consists entirely of case reports and small case series. No drug has been tested in a prospective trial for GS. Patient stratification by genotype is essential because prognosis and clinical course differ dramatically between types 1, 2, and 3, but no standardised treatment protocol exists. Funding for natural history studies and for any interventional trial is absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Pediatric Hematology/Oncology · 2010 · 13 citations · open access
Premature Birth, Respiratory Distress, Intracerebral Hemorrhage, and Silvery-gray Hair
AbstractSUMMARY: A preterm neonate, born to consanguineous parents, presented with respiratory distress, intracerebral hemorrhage, and a silvery-gray sheen of the hair and eyelashes. Griscelli syndrome (GS) type 3 was diagnosed after the detection of a novel homozygous mutation of the melanophilin gene. Thus, only the hypopigmentation, but not the patient's other clinical features, were attributable to this form of GS. Differential diagnosis of the various forms of GS must be performed as early as possible as GS2 is associated with a life threatening but curable immune disorder.
Clinical Case Reports · 2021 · 10 citations · open access
Griscelli Syndrome in a seven years old girl
AbstractIn this study, a case of Griscelli Syndrome (GS) in a 7 years old girl was reported. The patient initially presented with fever and pancytopenia in laboratory results; after ruling out the malignancies, she went under treatment with the diagnosis of infectious disease and was discharged after two weeks. Nevertheless, ten days after discharge, she developed new symptoms. Due to patient symptoms and general appearance, microscopic analysis of her hair shaft was done, and the abnormal distribution of pigments in the shaft was observed, indicating GS.
British Journal of Dermatology · 2016 · 8 citations
Further evidence for genotype-phenotype disparity in Griscelli syndrome
AbstractFirst described in 1978, Griscelli syndrome (GS) is a rare autosomal recessive disorder featuring pigmentary dilution of hair and skin.1 GS is caused by mutations in any of three genes encoding a tripartite protein complex essential for melanosome transport.2 GS1 (MIM214450) presents as hypomelanosis with primary neurological defects and is caused by mutations in MYO5A,3 and which also may be the same entity as Elejalde syndrome (MIM256710).4
This article is protected by copyright. All rights reserved.
Pigment International · 2019 · 1 citations · open access
Griscelli syndrome 3: a rare and mild variant
AbstractGriscelli syndrome is a multisystemic disorder. It is of three types with a common feature of pigmentary dilution. The clinical types depend on the gene involved leading to a varied presentation ranging from only pigmentary dilution and excellent prognosis in type 3 to a severe disease with multisystem involvement in type 2. Type 3 is the least reported variant. We describe a 23-year-old male with sporadic presence of light-colored skin and silver gray hair.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2007 · 0 citations
Faculty Opinions recommendation of Griscelli syndrome: a new phenotype with circumscribed pigment loss?
AbstractGriscelli syndrome is a rare genetic immunodeficiency disorder characterized by pigment dilution, recurrent cutaneous and pulmonary infections, neurological deterioration, hypogammaglobulinemia, and defective cell-mediated immunity. Mutations of three distinct genes have been described in Griscelli syndrome with different phenotypes. The disease is usually fatal by the first decade of life. We report a 20-year-old female with Griscelli syndrome with circumscribed pigment loss over thighs and abdomen in addition to diffuse pigment dilution. An accelerated phase, similar to that described in Chediak-Higashi syndrome, was also observed in our case in the form of neurological deterioration. Survival of the patient beyond the first decade of life in the absence of specific therapy was also a distinctive feature. PMID: 17498436
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
